Lixte Financial Statements From 2010 to 2025

LIXTW Stock  USD 0.04  0.0001  0.28%   
Lixte Biotechnology financial statements provide useful quarterly and yearly information to potential Lixte Biotechnology Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lixte Biotechnology financial statements helps investors assess Lixte Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lixte Biotechnology's valuation are summarized below:
Market Capitalization
39.5 M
There are over one hundred fifteen available fundamental ratios for Lixte Biotechnology, which can be analyzed over time and compared to other ratios. All traders should should check Lixte Biotechnology's last-minute fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to drop to about 881.5 K in 2025. Enterprise Value is likely to climb to about (5 M) in 2025
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 19.6 K, Other Operating Expenses of 6.1 M or EBITDA of 3.9 K, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 1.06. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Lixte Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.2 MM2.7 M
Slightly volatile
Other Current Liabilities379 K360.9 K172.2 K
Slightly volatile
Total Current Liabilities290.7 K360.9 K276.6 K
Slightly volatile
Cash5.1 M4.8 M2.5 M
Slightly volatile
Cash And Short Term Investments5.1 M4.8 M2.5 M
Slightly volatile
Common Stock Total Equity4.2 MM1.4 M
Slightly volatile
Common Stock Shares Outstanding1.6 M1.7 M40.4 M
Slightly volatile
Liabilities And Stockholders Equity5.2 MM2.7 M
Slightly volatile
Other Stockholder Equity59.1 M56.3 M27.2 M
Slightly volatile
Total Liabilities290.7 K360.9 K276.6 K
Slightly volatile
Total Current Assets5.1 M4.9 M2.7 M
Slightly volatile
Common Stock2462593.2 K
Slightly volatile
Property Plant And Equipment Net109115184
Slightly volatile
Accounts Payable169.4 K180.3 K165.5 K
Slightly volatile
Other Current Assets29.6 K31.2 K77.3 K
Slightly volatile
Property Plant And Equipment Gross109115184
Slightly volatile
Short and Long Term Debt Total80 K90 K98.1 K
Slightly volatile
Short Term Debt193.4 K360.9 K195 K
Slightly volatile
Short Term Investments89 K93.7 K107.6 K
Very volatile
Net Receivables12.3 K12.9 K78.5 K
Slightly volatile
Inventory58.1 K70.1 K60.3 K
Slightly volatile
Current Deferred Revenue189.7 K180.7 K80.5 K
Slightly volatile
Capital Surpluse26.5 M36.6 M24 M
Slightly volatile
Net Working Capital4.2 M4.6 M2.6 M
Slightly volatile
Non Currrent Assets Other100 K89.7 K46.2 K
Slightly volatile
Capital Stock2.8 M3.2 M3.4 M
Slightly volatile

Lixte Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses6.1 M5.9 M3.3 M
Slightly volatile
Total Operating Expenses6.1 M5.9 M3.3 M
Slightly volatile
Depreciation And Amortization6.1 M5.9 M2.1 M
Slightly volatile
Selling General Administrative5.1 M4.8 M2.3 M
Slightly volatile
Research DevelopmentMMM
Pretty Stable
Gross Profit160 K180 K196.2 K
Slightly volatile
Interest Income12.4 K23.6 K7.9 K
Slightly volatile
Selling And Marketing Expenses3.4 M3.8 M4.1 M
Slightly volatile

Lixte Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow5.1 M4.8 M2.5 M
Slightly volatile
Begin Period Cash Flow6.5 M6.2 M2.4 M
Slightly volatile
Depreciation109115147
Slightly volatile
Stock Based Compensation858.4 K889.2 K846 K
Slightly volatile
Dividends Paid1.7 K1.8 K8.1 K
Slightly volatile
Total Cashflows From Investing Activities83.3 K93.7 K102.1 K
Slightly volatile
Other Cashflows From Investing Activities83.3 K93.7 K102.1 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio56.0963.168.7956
Slightly volatile
Dividend Yield2.0E-43.0E-42.0E-4
Slightly volatile
Average Payables117.9 K184.4 K164 K
Slightly volatile
Stock Based Compensation To Revenue2.22.472.6968
Slightly volatile
Capex To Depreciation0.850.530.5269
Very volatile
EV To Sales55.9862.9968.6713
Slightly volatile
Sales General And Administrative To Revenue3.023.393.7013
Slightly volatile
Research And Ddevelopement To Revenue8.379.4110.2636
Slightly volatile
Cash Per Share2.371.983.7858
Slightly volatile
Income Quality0.540.760.7013
Very volatile
Current Ratio12.9712.369.1027
Slightly volatile
Capex Per Share0.00.00.0
Very volatile
Average Receivables7.8 K8.3 K13.7 K
Slightly volatile
Revenue Per Share0.210.230.2521
Slightly volatile
Interest Debt Per Share0.0530.05050.0147
Slightly volatile
Debt To Assets1.551.741.8996
Slightly volatile
Ebt Per Ebit1.161.151.0812
Pretty Stable
Quick Ratio12.9712.369.0894
Slightly volatile
Net Income Per E B T0.790.90.9678
Slightly volatile
Cash Ratio12.6612.058.4421
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.016
Slightly volatile
Debt Ratio1.551.741.8996
Slightly volatile
Price Sales Ratio56.0963.168.7956
Slightly volatile
Asset Turnover0.260.30.3277
Slightly volatile

Lixte Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap881.5 K927.9 K25.8 M
Slightly volatile

Lixte Fundamental Market Drivers

Cash And Short Term Investments4.2 M

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue180.7 K189.7 K
Stock Based Compensation To Revenue 2.47  2.20 
Sales General And Administrative To Revenue 3.39  3.02 
Research And Ddevelopement To Revenue 9.41  8.37 
Revenue Per Share 0.23  0.21 
Ebit Per Revenue(11.91)(12.50)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.